SUN PHARMACEUTICAL INDUSTRIES LTD.

Sun Pharmaceutical Industries Ltd has announced the closure of its trading window for dealing in the company's shares. This closure will be effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026. The specific date for the Board Meeting to approve these results will be communicated later. This measure is in accordance with the company's Code of Conduct for Prohibition of Insider Trading, aimed at preventing potential misuse of unpublished price-sensitive information.

Sun Pharmaceutical Industries Limited has announced the acquisition of 100% outstanding shares of Innovcare Lifesciences Private Limited for a cash consideration of approximately ₹271.2 Crores. Innovcare Lifesciences is engaged in the marketing, distribution, and sale of pharmaceutical drugs, nutraceutical, and cosmeceutical products. The acquisition is a strategic investment aimed at strengthening Sun Pharma's product portfolio. The deal is expected to be completed by July 31, 2026. Innovcare reported revenues of INR 94.06 crores for FY 2025-26.

Sun Pharmaceutical Industries Ltd. has announced that its Independent Director, Mr. Gautam Doshi, has been arrested. The company has clarified that this matter is unrelated to Sun Pharma and is not expected to impact the company's operations or its Board processes. Sun Pharma will continue to monitor the situation and take appropriate actions as developments unfold.

Sun Pharmaceutical Industries Ltd has announced July 7, 2026, as the record date for determining shareholder entitlement to a final dividend of ₹5 per equity share for the financial year 2025-26. The 34th Annual General Meeting (AGM) is scheduled for July 31, 2026, to be held via video conferencing. The dividend payment, if approved by shareholders at the AGM, is expected on or before August 7, 2026. Shareholders are advised to update their contact details and submit any necessary documents for TDS on dividend by the record date.

Sun Pharmaceutical Industries Ltd has announced July 7, 2026, as the record date to determine shareholder eligibility for its final dividend of ₹5 per equity share for the financial year 2025-26. The 34th Annual General Meeting (AGM) is scheduled for July 31, 2026, where the dividend will be proposed for shareholder approval. If approved, the dividend payment is expected by August 7, 2026. Shareholders are advised to update their contact details and submit any necessary TDS-related documents by the record date.

Sun Pharmaceutical Industries Ltd has announced its 34th Annual General Meeting (AGM) will be held on Friday, July 31, 2026, at 4:00 p.m. IST via Video Conferencing. The company has also set Tuesday, July 7, 2026, as the record date for determining shareholder eligibility for a final dividend of ₹5 per equity share for the financial year 2025-26. The dividend payment, if approved at the AGM, is expected on or before Friday, August 7, 2026. Shareholders are advised to update their contact details for timely communication and dividend credit. Tax implications on the dividend will apply, with relevant documentation to be submitted by the record date.

Sun Pharmaceutical Industries Ltd. has submitted an application to stock exchanges on May 26, 2026, seeking approval for reclassification from the 'Promoter Group' category to the 'Public' category. This action is in accordance with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This follows earlier intimations on May 14 and May 22, 2026.

Sun Pharmaceutical Industries will present updated results from the pivotal CK-301-101 trial of UNLOXCYT™ (cosibelimab-ipdl) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The data shows a 50% objective response rate in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC), including 27% complete responses. The median duration of response was not yet reached after a median follow-up of 31 months. The safety profile was consistent with previous analyses.

Sun Pharmaceutical Industries Ltd's board approved requests for reclassification of certain promoter group individuals to the 'Public' category, subject to necessary approvals. The board also approved and adopted the revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, effective from June 1, 2026, available on the company's website.

Sun Pharmaceutical Industries Ltd. has recommended a final dividend of ₹5 per equity share of Re. 1 each for the financial year 2025-26, subject to shareholder approval at the 34th Annual General Meeting. This decision was made during the Board of Directors meeting held on May 22, 2026, where the audited financial results for the quarter and year ended March 31, 2026, were also approved. The dividend, once approved, will be paid within the timeline prescribed under the Companies Act, 2013.